Project Grant R43TR004890
Award Date
1/1/24
Completion Date
12/31/24
Dollars Obligated
$298K
Federal Agency
National Center for Advancing Translational Sciences
Federal Grant Program
93.350
Assistance Type
Project Grant
Place of Performance
미국 뉴욕
Similar Awards
This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training Program (CFDA 93.859), provides $302,605 to Chimerna Therapeutics, Inc. to develop innovative methods for producing and functionalizing circular RNAs (circRNAs) to improve their endosomal escape and therapeutic delivery. The key objectives are to: 1) Optimize a bacterial expression system to enhance site-specific amino functionalization of circRNAs, and 2)...
This federal Project Grant award from the National Center for Advancing Translational Sciences (NCATS) in the amount of $419,398 will fund research to accelerate the translation of oligonucleotide therapeutics by enhancing their delivery. The award, with a period of performance from June 16, 2025 to June 15, 2027, aims to develop a small molecule solution to overcome the key barrier of biological membrane penetration that currently limits the clinical use of oligonucleotide-based therapies, such...
The National Center for Advancing Translational Sciences (NCATS), under CFDA program 93.350, awarded a $459,598 Project Grant to Vindhya Data Science Inc., a woman-owned small business, to develop the BIOCLIN precision medicine software platform. This platform is designed to enable RNA sequencing-based biomarker clinical trials by addressing key challenges in bioinformatics analysis, regulatory validation, and the lack of supportive software platforms. The Phase I grant will fund user research...
The National Center for Advancing Translational Sciences (NCATS), under the CFDA Program 93.350, awarded a $338,997 Project Grant to Mabswitch Inc. effective January 1, 2024 to December 31, 2024. The project aims to develop "LENTISAFE LIGANDS: MILD-ELUTION IMMUNOAFFINITY LIGANDS FOR ENRICHMENT AND PURIFICATION OF LENTIVIRAL VECTORS." The goal is to create switchable affinity ligands that can be used to selectively isolate and enrich functional lentiviral vectors from production...
The National Science Foundation (NSF) awarded a $274,980 SBIR Phase I Project Grant to Cisterna Biologics, Inc. to develop a novel platform for cost-efficient mRNA production in yeast. The project aims to transform yeast cells into efficient mRNA factories and utilize advanced chromatographic techniques for purification, with the goal of reducing mRNA manufacturing costs by 90% compared to current in vitro transcription methods. Key technical objectives include demonstrating stable mRNA fusion...
This $350,000 Project Grant award from the National Center for Advancing Translational Sciences (NCATS), under the 93.350 CFDA program, supports the development of the Codomax EPI-MAX platform. This integrated omics and computational technology leverages cellular stress responses to enhance the production of difficult-to-express therapeutic proteins, with a focus on improving secretion and preventing aggregation in the Pichia pastoris expression system. The key products or services to be...
This Phase I Small Business Innovation Research (SBIR) grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) awarded $350,000 to Cisterna Biologics, Inc. to develop a novel process for rapid and ultra-pure mRNA production. The project aims to generate high-quality mRNA essential for therapeutic applications by optimizing the use of cold-adapted RNA polymerases and a proprietary purification technology to...
This federal Project Grant award from the National Center for Advancing Translational Sciences (NCATS), under CFDA 93.350, provides $349,171 to Cellchorus Inc. to develop an integrated computer vision system called LF-TIMING (Label-Free TIMING). The goal is to enable large-scale, label-free profiling of cell-cell interactions, particularly between immune cells and tumor cells. The LF-TIMING system will leverage deep neural networks to accurately analyze phase-contrast video recordings,...
The National Center for Advancing Translational Sciences (NCATS) awarded a $275,000 Project Grant (CFDA 93.350) to Nectagen Inc. to develop bioprocess-compatible, second-generation nanoclamp affinity resins for the efficient purification of plasma-based therapeutic proteins. The goal is to identify panels of nanoclamps to 5 industrially relevant plasma-based therapeutics, select lead candidates, and optimize the resins for maximum recovery and purity from plasma samples. This project aims to...
This Project Grant awarded by the National Center for Advancing Translational Sciences (NCATS), under CFDA Program 93.350, provides $2,149,781 in funding to Rejuvenation Technologies Inc. (RTI) to develop advanced tools for the clinical translation of intravenously-infused RNA lipid nanoparticle (LNP) therapeutics. Specifically, the grant supports RTI's efforts to: Develop high-sensitivity analytical capabilities for their TERT mRNA LNP therapeutic drug product Conduct high-sensitivity...